Sanofi SA vs Upwork Inc — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Upwork Inc trades at $8.24 (market cap $1.04B). The key difference: Sanofi SA is far larger — about 100.1× Upwork Inc's market cap, and Sanofi SA pays a 5.61% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| SNY | UPWK | |
|---|---|---|
Market Cap | $104.06B | $1.04B |
Sector | Health | Industrials |
52-Week High | $52.34 | $22.11 |
52-Week Low | $41.33 | $7.84 |
Enterprise Value | $124.09B | $802.40M |
Dividend Yield | 5.61% | — |
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Upwork (UPWK) is trading at $8.32, down 5.35% on the day, with a bearish technical signal and recent earnings volatility. The company maintains strong profitability metrics including a 77.21% gross margin and 12.93% net income margin, though Q2 2026 earnings beat was overshadowed by weak guidance. Recent news highlights multiple securities fraud investigations alongside AI integration developments.
The stock presents a mixed outlook with attractive valuation multiples (P/E 10.67, P/S 1.44) but faces headwinds from AI disruption and legal scrutiny. Analyst consensus leans bullish with a $9.00 price target, though technical indicators suggest near-term pressure with support at $8.00.
Trailing returns across standard periods
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →